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CORRESPONDENCE
Letters to the Editor
Efficacy and
Safety in Clinical Trials
In their rebuttal to my essay “Efficacy and Safety in Clinical Trials
in Cardiovascular Disease” (1), Granger and McMurray (2) fired a
series of rockets that missed the target.
To criticize previously identified so-called disease markers
(premature ventricular complexes, cardiac output, symptom relief,
plasma norepinephrine) because they do not track with disease
progression is misdirected, because we all agree these are not
fundamental to the disease process. As I have stressed, and
Granger and McMurray seem to agree, structural markers are far
more discriminating. To suggest that not all therapies that slow
disease progression improve outcome is equally disingenuous; that
is why I have stressed that safety as well as efficacy must be
addressed.
Granger and McMurray avoid the real issue. Our treatments are
aimed at slowing or aborting a disease process, but they are
administered to individuals whose well-being is also dependent on
other factors. Granger and McMurray seem interested only in the
net effect. I am interested in separating efficacy from safety. They
defend against such attempts, stating that “using measures of
disease progression . . . [should be] rigorously resisted.”
Rather than hiding behind their self-proclaimed inability to
“understand the disease” or “the exact mechanism of benefit,”
Granger and McMurray would better serve the cardiovascular
community by advocating that mechanisms be carefully addressed
in future clinical trials so as to gain such understanding. Docu-
mentation of the benefit of therapies for early stages of disease
requires assessment of disease progression, and strategies for
management of advanced disease may require separate and perhaps
individualized optimization of efficacy and safety. It is time to
accelerate the learning process, not to retreat into the past comfort
of simple mortality/morbid events trials.
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Reply
We were pleased to see that Dr. Cohn (1) accepts the need to
examine the effect of treatment on mortality, although he
chooses to see this as a measure of safety rather than efficacy.
We do not know how to decide which surrogate measure “tracks
with disease progression.” Dr. Cohn currently favors a structural
marker—a few years ago, norepinephrine or ejection fraction
might have been the popular choice. Who is to say that in a few
more years structural changes will go the same way as those
previous favorites? Moreover, some highly effective treatments
(like implantable cardioverter-defibrillators) do not affect struc-
ture or the disease process but do reduce mortality, underscor-
ing the limitations of predicting treatment effect with disease
markers.
Dr. Cohn’s vision is, of course, utopian. If only we could do
what he wanted—but we have not yet managed to do so and have
failed miserably when we have tried. In the end, however, we agree
with Dr. Cohn’s call to design trials to better understand disease
process and individual response to therapy. He rightly points out
that our ultimate goal of individualized medicine will require much
better understanding of patient response and safety. In doing so,
however, even larger trials will be necessary, and ultimately
measuring important clinical outcomes will always be necessary to
determine the net effect that defines what matters in clinical care.
In the meantime, as long as Dr. Cohn accepts the need for
assessment of “safety,” the debate is more of a philosophical than
practical one—the same large trials with the same clinical out-
comes will be needed.
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Clinical Implications of the
PROTECT–TIMI-30 Trial
We would like to congratulate Gibson et al. (1) for the completion
of the recently reported PROTECT–TIMI-30 (Randomized
Trial to Evaluate the Relative PROTECTion against Post-PCI
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Microvascular Dysfunction and Post-PCI Ischemia among Anti-
Platelet and Anti-Thrombotic Agents–Thrombolysis In Myocar-
dial Infarction-30) trial, in which patients with moderate to
high-risk acute coronary syndrome (ACS) undergoing percutane-
ous coronary intervention (PCI) were randomly allocated to receive
eptifibatide with either unfractionated heparin or enoxaparin
versus bivalirudin monotherapy. Although this study adds insight-
ful information to the ongoing debate on the comparison of direct
thrombin inhibitor alone versus the association of glycoprotein
(GP) IIb/IIIa inhibitors and indirect antithrombin agents as
adjunctive treatment during PCI, it also puzzles the reader with
the contrasting data on efficacy provided by the primary and
secondary end points.
The post-PCI coronary flow reserve (CFR), quantified through
the corrected Thrombolysis In Myocardial Infarction (TIMI)
frame count, has to the best of our knowledge never been shown to
correlate with outcomes in patients with non–ST-segment eleva-
tion ACS. Moreover, its agreement with Doppler-derived CRF in
this setting has been questioned (2). In contrast, the 25% relative
risk reduction in the composite of death or myocardial infarction
(MI) at 48 h and the significant 35% relative decrease in the rate
of patients showing post-PCI creatine kinase-myocardial band
(CK-MB) elevation among subjects (n  624; 73%) CK-MB–
negative at baseline in the group allocated to eptifibatide seem to
support the additive value of complete platelet inhibition in such a
setting (3). We believe that some methodological issues beyond
those discussed by Gibson et al. (1) may help explain the
paradoxical results of the primary end point when put into the
context of the results reported for the secondary outcomes.
Coronary flow reserve after the procedure could not be analyzed
according to the intention-to-treat principle in the study because
patients who sustained abrupt vessel closure, emergent coronary
bypass graft surgery, or thrombotic closure with bailout to eptifi-
batide had to be excluded (n  103; 12% of the enrolled
population). It thus remains possible that patients at relatively
lower risk have been selected for the primary end point assessment
in whom no or minor benefit from GP IIb/IIIa inhibitors on
microcirculation may be expected. It would be of utmost interest to
know the rate of major adverse events in this excluded fraction of
patients, stratified according to the randomization scheme and as
compared to the patient group in whom primary end point analysis
could be accomplished. This may help to reconcile the apparently
contrasting data between the primary end point (based on 88% of
the enrolled population) and secondary outcome (based on the
whole population) results in the study.
Finally, the investigators comment in the discussion section that
the risk of death or MI was significantly reduced among eptifi-
batide patients who were pretreated for 6 h with clopidogrel
before PCI, but they fail to report throughout the study the actual
figures for the observed event rates in this subset of patients despite
the fact that this was a prespecified secondary analysis and that
randomization was stratified according to prior use of thienopyri-
dines. We believe that this information may help to put
PROTECT–TIMI-30 findings in perspective, especially consid-
ering that 40% of ACS patients may undergo PCI after upfront
blockade of the P2Y12 receptor in current clinical practice (4).
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We thank Dr. Valgimigli et al. for their careful review of the
PROTECT–TIMI-30 (Randomized Trial to Evaluate the Rela-
tive PROTECTion against Post-PCI Microvascular Dysfunction
and Post-PCI Ischemia among Anti-Platelet and Anti-
Thrombotic Agents–Thrombolysis In Myocardial Infarction-30)
study (1). The corrected Thrombolysis In Myocardial Infarction
(TIMI) frame count (cTFC) measures the time that it takes for
blood to traverse the entire length of the artery and reflects the
average velocity throughout the entire length of the artery. In
contrast, a Doppler velocity wire measures the velocity at a single
point in the artery. As shown in the angiogram that accompanies
our report (1), blood velocity can vary significantly throughout the
length of the artery, and it is therefore no surprise that the cTFC
(average velocity) and Doppler velocity (velocity at a single point)
measures may be discordant in their assessment of basal blood
velocity given the heterogeneity in velocity throughout an artery.
The ability to speed up this basal blood velocity is the coronary flow
reserve (CFR). The cTFC measures how much faster blood passes
through the same length of the entire artery before and after
adenosine. In contrast, a Doppler velocity wire measures whether the
velocity accelerated at a single point in the artery. As opposed to
potential discrepancies in basal velocity, the CFR based on the cTFC
has been related to Doppler velocity measures (r  0.88) (2).
Although the basal cTFC has been related to mortality and
post-percutaneous coronary intervention (PCI) events, Valgimigli
et al. correctly point out that CFR by the cTFC method has not
been related to clinical outcomes (3), and it should be added that
Doppler velocity measures have not been related to outcomes as
well. In contrast, the TIMI myocardial perfusion grade (TMPG)
was related to ischemic and clinical outcomes following PCI (3).
Dr. Valgimigli et al. point out that CFR could not be assessed
in patients with a failed PCI procedure in whom there was abrupt
vessel closure, emergency coronary artery bypass graft surgery, or
thrombotic closure with bailout to eptifibatide. To account for
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